openPR Logo
Press release

Porphyria Treatment Market Latest Trends, Future Growth, Industry Analysis, Development, Opportunities, and Forecasts to 2031 | Recordati Rare Diseases Inc, AmerisourceBergen Corporation, Alnylam Pharmaceuticals, Inc

11-18-2024 05:16 PM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

DataM Intelligence

DataM Intelligence

The Porphyria Treatment Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/porphyria-treatment-market

What is the projected growth rate (CAGR) of the Global Porphyria Treatment market from 2024 to 2031, and what is the market value expected to change by 2031?

The global porphyria treatment market is growing at a CAGR of 9.2% during the forecast period (2024-2031).

Porphyria refers to a group of rare genetic disorders caused by the accumulation of porphyrins, which are essential for the production of hemoglobin, the protein responsible for carrying oxygen in the blood. The symptoms of porphyria can vary based on the type of disorder. Acute porphyrias primarily affect the nervous system and can cause symptoms such as abdominal pain, neurological issues, and psychiatric symptoms. Cutaneous porphyrias, on the other hand, mainly affect the skin, leading to sensitivity to sunlight, blisters, and skin damage. While there is no cure for porphyria, treatment options are available to manage symptoms and prevent attacks. These may include avoiding known triggers, taking medications to alleviate symptoms, administering heme intravenously, or undergoing phlebotomy (blood removal) to reduce iron levels in the body. The specific treatment approach depends on the type of porphyria diagnosed.

Market Dynamics

Advancements in the treatment of congenital erythropoietic porphyria (CEP) are expected to significantly drive market growth. The primary curative options for CEP involve bone marrow or hematopoietic stem cell transplantation, but these procedures come with high morbidity and mortality risks, necessitating careful evaluation and management. For patients who are not candidates for transplantation, the main treatment approach focuses on avoiding sun and light exposure to manage symptoms.

In cases of severe hemolysis, patients may require frequent blood transfusions, typically every two to four weeks, which help reduce photosensitivity by suppressing erythropoiesis and lowering porphyrin production. Additionally, patients with hematocrit levels above 35% may benefit from iron chelation therapy to address iron overload. Research is ongoing to explore new treatment options, including genetically modified hematopoietic stem cells and proteasome inhibitors, which may offer more effective and less invasive alternatives. These developments, along with continued investigation into alternative therapies, are expected to drive the market for CEP treatments during the forecast period.

List of the Key Players in the Porphyria Treatment Market: Recordati Rare Diseases Inc., AmerisourceBergen Corporation, Alnylam Pharmaceuticals, Inc., CLINUVEL PHARMACEUTICALS LTD, sanofi-aventis U.S. LLC, Concordia Pharmaceuticals Inc., AdvaCare Pharma and AuroMedics Pharma LLC.

Research Process:

Both primary and secondary data sources have been used in the global Porphyria Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Porphyria Treatment Market:

By Disease Type (Acute Porphyrias, and Cutaneous Porphyrias)

By Diagnosis (Blood test, Urine test, Genetic test, Others)

By Treatment (Medications, Phlebotomy, and Others)

By End-user (Hospitals, Blood Centers, Others)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)

Regional Breakout:

The global Porphyria Treatment Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

✫ North America (U.S., Canada, Mexico)

✫ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

✫ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

✫ South America (Colombia, Brazil, Argentina, Rest of South America)

✫ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Year End Discounts on Premium Report:- https://www.datamintelligence.com/buy-now-page?report=porphyria-treatment-market

This Report Unveils:

✔ Go to Market Strategy- A roadmap to successfully product launch or service in the target market.

✔ Gain a clear picture of the market's health and growth trajectory through neutral analysis.

✔ Deep Market Insights delve into development trends, competitor landscape, supply and demand dynamics, brand share & pricing analysis year-over-year growth patterns, and key players' performance.

✔ Upon request, we can provide customized reports focusing on specific regions or countries, offering a granular view of their markets.

✔ Identify high-potential niche segments and regions poised for significant expansion.

✔ Analysis of Market Size (historical and forecast) Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM) to understand the market's overall size and your achievable market share.

✔ Gain a comprehensive understanding of the competitive landscape, including market share distribution, key players (innovators, startups, laggards, and pioneers), and their respective strengths and weaknesses.

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Porphyria Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Porphyria Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the Porphyria Treatment market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the Porphyria Treatment market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/porphyria-treatment-market

Frequently Asked Questions

☞ What is the expected growth rate of the global Porphyria Treatment market for the forecast period?

☞ What are the key driving factors that are responsible to shape the fate of the Porphyria Treatment market during the forecast period?

☞ What will be the overall size of the market during the analysis period?

☞ What are the prominent market trends which influence the development of the Porphyria Treatment market across various regions?

☞ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☞ What are the challenges and threats that are likely to act as a barrier to the growth of the Porphyria Treatment market?

☞ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Porphyria Treatment Market Latest Trends, Future Growth, Industry Analysis, Development, Opportunities, and Forecasts to 2031 | Recordati Rare Diseases Inc, AmerisourceBergen Corporation, Alnylam Pharmaceuticals, Inc here

News-ID: 3741827 • Views:

More Releases from DataM intelligence 4 Market Research LLP

Global Omega-3 Concentrates Market 2025 - Latest Trends, Innovations & Growth Forecast
Global Omega-3 Concentrates Market 2025 - Latest Trends, Innovations & Growth Fo …
The global omega-3 concentrates market reached US$3.02 billion in 2024 and is expected to reach US$ 5.11 billion by 2032, growing at a CAGR of 6.8% during the forecast period 2025-2032. The Omega-3 Concentrates Market refers to the global industry involved in the production, processing, and commercialization of highly concentrated omega-3 fatty acids, primarily EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), derived from sources like fish oil, algae, krill, and plant
USA Medium Chain Triglycerides Market Accelerates - Valued at USD 871.21 Million in 2025, On Track to Reach USD 1,296.03 Million by 2032
USA Medium Chain Triglycerides Market Accelerates - Valued at USD 871.21 Million …
DataM Intelligence announces the release of its market report, "Medium Chain Triglycerides Market: Size, Share, Trends & Forecast 2025-2032." According to the analysis, the Medium Chain Triglycerides Market (MCT Market) in the USA is valued at USD 871.21 million in 2025. It is projected to grow at a CAGR of 5.09%, reaching USD 1,296.03 million by 2032. The increase in consumer demand for clean-label, energy-boosting, and functional food ingredients is
United States Autoimmune Treatment Market 2025 | Growth Drivers, Key Players & Investment Opportunities
United States Autoimmune Treatment Market 2025 | Growth Drivers, Key Players & I …
Market Size and Growth The Global Autoimmune Treatment Market is predicted to reach at a Significant CAGR during the forecast period (2024-2031) Key Development: United States: Recent Industry Developments ✅ October 6, 2025 - Mary Brunkow and Fred Ramsdell (USA) and Shimon Sakaguchi (Japan) were awarded the Nobel Prize in Physiology or Medicine for their pioneering research on regulatory T cells and the FOXP3 gene, laying the groundwork for over 200 clinical trials
United States Atherosclerosis Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities
United States Atherosclerosis Drugs Market 2025 | Growth Drivers, Key Players & …
Market Size and Growth Global Atherosclerosis Drugs Market reached US$ 26.4 billion in 2023 and is expected to reach US$ 32.5 billion by 2031 growing with a CAGR of 2.6% during the forecast period 2024-2031. Key Development: United States: Recent Industry Developments ✅ In October 2025, Amgen announced a significant move by offering its cholesterol-lowering drug, Repatha, directly to U.S. consumers at a 60% discount, pricing it at $239 per month. This initiative aims

All 5 Releases


More Releases for Porphyria

What's Driving the Acute Intermittent Porphyria Market 2025-2034: Impact Of Risi …
What Are the Projections for the Size and Growth Rate of the Acute Intermittent Porphyria Market? There has been a robust growth in the market size of acute intermittent porphyria in the past few years. The market that was valued at $4.37 billion in 2024, is projected to increase to $4.66 billion in 2025, marking a compound annual growth rate (CAGR) of 6.7%. Factors such as increasing healthcare spending, a surge
Acute Intermittent Porphyria Market Acute Intermittent Porphyria Treatments, Siz …
According to a new report published by CoherentMI The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. The Global Acute Intermittent Porphyria Market has recently been analyzed and explored by CoherentMI in their latest market research report. The
Enhance Genetic Testing Module for Acute Intermittent Porphyria
The "Acute Intermittent Porphyria Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats,
Swedish Porphyria Therapeutics Market to Signify Strong Growth by 2023-2029
The Swedish Porphyria Therapeutics Market size is expected to grow at an annual average of CAGR 73% during the forecast period (2023-2029). Swedish porphyria is a rare, inherited disorder that mainly affects the skin and nervous system. The signs and symptoms of this disorder can vary from person to person. Some people with Swedish porphyria may have mild symptoms, while others may have more serious problems. And Swedish porphyria is
Porphyria Targeting Therapies Market, 2021-2030
Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market, 2021-2030” report to its list of offerings. Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can
Porphyria Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results | Alny …
Porphyria is a group of disorders including cutaneous porphyria and acute porphyria. Cutaneous porphyria affects the skin while acute porphyria affects the nervous system. Porphyria cutanea tarda is the most common type of porphyria prevalent in the U.S. Download the sample report at: https://www.pharmaproff.com/request-sample/1043 The common symptoms of porphyria are abdominal pain, chest pain, increased blood pressure, increased heart rate, muscle weakness, cramping, blisters, itching, swelling, constipation, vomiting, mental disorders,